Figure 7
Figure 7. PRAME CTLs can be generated from HLA-A*02+ CML patients. (A) Frequency of IFNγ CTLs specific for ALY (top graph), SLY (middle graph), and VLD peptides (bottom graph) in 6 HLA-A*02+ CML patients. (B) PRAME CTLs produced IFNγ+ SFC in response to PRAME peptides and to autologous CML blasts. In addition, CTLs reacting against the ELA peptide (■) generated from the same patient did not produce IFNγ+ SFC when cocultured with autologous CML blasts. (C) PRAME CTLs produced IFNγ in response to autologous CML blasts but not to CML blasts from a PRAME+/HLA-A*02− patient (patient 8).

PRAME CTLs can be generated from HLA-A*02+ CML patients. (A) Frequency of IFNγ CTLs specific for ALY (top graph), SLY (middle graph), and VLD peptides (bottom graph) in 6 HLA-A*02+ CML patients. (B) PRAME CTLs produced IFNγ+ SFC in response to PRAME peptides and to autologous CML blasts. In addition, CTLs reacting against the ELA peptide (■) generated from the same patient did not produce IFNγ+ SFC when cocultured with autologous CML blasts. (C) PRAME CTLs produced IFNγ in response to autologous CML blasts but not to CML blasts from a PRAME+/HLA-A*02 patient (patient 8).

Close Modal

or Create an Account

Close Modal
Close Modal